Compare NBIX & PNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | PNW |
|---|---|---|
| Founded | 1992 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.1B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | PNW |
|---|---|---|
| Price | $149.94 | $99.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 15 |
| Target Price | ★ $180.91 | $100.21 |
| AVG Volume (30 Days) | ★ 1.1M | 820.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.58% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | 0.27 |
| Revenue | $161,626,000.00 | ★ $5,339,939,000.00 |
| Revenue This Year | $24.73 | $5.15 |
| Revenue Next Year | $13.14 | $6.89 |
| P/E Ratio | ★ $77.03 | $372.07 |
| Revenue Growth | ★ 977.51 | 4.20 |
| 52 Week Low | $115.66 | $85.32 |
| 52 Week High | $160.18 | $104.92 |
| Indicator | NBIX | PNW |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 40.67 |
| Support Level | $133.96 | $86.28 |
| Resistance Level | $158.92 | $104.22 |
| Average True Range (ATR) | 3.63 | 1.86 |
| MACD | 2.00 | -0.45 |
| Stochastic Oscillator | 98.20 | 5.57 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.